Royal Philips announced FDA 510(k) clearance of its next-generation reusable Philips SpO₂ clip sensor, reinforcing the company’s ongoing commitment to providing clinicians with trusted oxygen saturation measurements that… read more.
Having normal blood pressure, no diabetes and not smoking was associated with living nearly 13 years longer without dementia, according to a study published August 5, 2026, in Neurology® Open… read more.
Emily P. Hyle, MD, and Kenneth A. Freedberg, MD, of the Medical Practice Evaluation Center within the Department of Medicine at Mass General Brigham, are the lead and senior authors of a… read more.
Bristol Myers Squibb announced that the FDA has approved ZENBEXUS (iberdomide) in combination with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd) for the treatment of adult patients with multiple… read more.
Daiichi Sankyo and AstraZeneca announced that Enhertu (trastuzumab deruxtecan) in combination with pertuzumab has been approved in China for the first-line treatment of adult patients with unresectable or… read more.
A multi-institutional study led by researchers at Children’s Hospital of Philadelphia (CHOP) found that telemedicine is becoming increasingly common for problem-based primary care, particularly for children with endocrine… read more.
4 August 2026 – GE HealthCare announced the introduction of the Logiq e family, featuring Logiq e Xi and Logiq e Si, two compact laptop ultrasound systems designed… read more.
Nightmares are among the most agonizing symptoms of post-traumatic stress disorder (PTSD) – a condition that can develop after exposure to severe traumatic experiences, such as disasters, serious… read more.
Abbott announced a first-of-its-kind partnership with Google Health to redefine how people understand and manage their health. By combining glucose insights from Abbott’s Lingo biowearable with Google’s expertise… read more.
Idorsia Ltd announces that the US Drug Enforcement Administration (DEA) will publish a proposed rule to reclassify dual orexin receptor antagonists (DORAs) from Schedule IV to Schedule V… read more.
NICE: Finerenone can be used, within its marketing authorisation, as an option to treat symptomatic chronic heart failure with preserved or mildly reduced ejection fraction in adults. Why… read more.
Bavarian Nordic A/S announced that the European Commission has adopted the recent Committee for Medicinal Products for Human Use (CHMP) positive opinion recommending the approval of a type… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
